Inhibitory experiments with the tyrosine kinase inhibitor imatinib led to an upregulation of SHIP1 at the mRNA and protein level in both BCR-ABL1-positive CML and B-ALL cells [11]. This evidence concerns the gene INPP5D and chronic myelogenous leukemia, BCR-ABL1 positive.